HIV Cure Research Information Sheet
Research into curing HIV infection is ever-changing as new discoveries are made and scientists report additional rare — but informative — cases of individuals likely cured of HIV.
ANEA and TAG Stand in Solidarity with Demonstrators Fighting to Save PEPFAR
The ACT NOW: END AIDS Coalition (ANEA) and Treatment Action Group (TAG) are proud to stand in solidarity with activists demonstrating today at the U.S. Capitol demanding that the U.S. government restore full funding to the President’s Emergency Plan for AIDS Relief (PEPFAR)
TAG Fiercely Condemns the New Administration’s War on Science
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.
2025 Pre-CROI Community HIV Cure Research Workshop
The 2025 Pre-CROI Community HIV Cure Research Workshop will take place on Saturday, March 8 in San Francisco.
TAG Joins Allies at State Department to Demand Full Restoration of US Support for Global AIDS Programs
Treatment Action Group (TAG) fiercely condemns the new presidential administration’s deadly and hateful attack on people living with HIV and their communities at home and around the world.
TAG Executive Director Warns: “They Don’t Care If We Live or Die”
This title of this page is one of the quotes by Mark Harrington from his recent appearance on +Life Media with TAG board member Karl Schmid. We rate this video absolutely must watch!
TAG Condemns Planned U.S. Withdrawal from WHO
Treatment Action Group (TAG) is appalled by President Donald Trump’s executive order Monday signaling the United States will be withdrawing from the World Health Organization (WHO).
TAGline November 2024
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.
Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short
TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.
2023 Annual Report
We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.